Iovance Biotherapeutics Inc Earnings

The next earnings date for Iovance Biotherapeutics Inc is November 6, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Iovance Biotherapeutics Inc Earnings

Report Date	Estimated Earnings Per Share
11/06/2025	$-0.26

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Iovance Biotherapeutics Inc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
08/07/2025	---	$-0.33	-16.69%
05/07/2025	Before Market	$-0.36	14.29%
02/26/2025	Before Market	$-0.26	2.84%
11/07/2024	After Market	$-0.28	6.67%
08/08/2024	After Market	$-0.34	2.86%
05/09/2024	After Market	$-0.42	0.00%
02/28/2024	After Market	$-0.45	-4.65%
11/07/2023	After Market	$-0.46	-2.22%
08/08/2023	After Market	$-0.47	41.25%
05/09/2023	After Market	$-0.50	32.43%
02/28/2023	After Market	$-0.64	0.00%
11/03/2022	After Market	$-0.63	1.56%
08/04/2022	After Market	$-0.63	-3.28%
05/05/2022	After Market	$-0.58	9.38%
02/24/2022	After Market	$-0.63	-12.50%
11/04/2021	After Market	$-0.55	-3.77%
08/05/2021	After Market	$-0.53	-3.92%
05/06/2021	After Market	$-0.51	-4.08%
02/25/2021	After Market	$-0.47	-6.82%
11/05/2020	After Market	$-0.40	13.04%
08/06/2020	After Market	$-0.47	11.32%
05/05/2020	After Market	$-0.55	-7.84%
02/25/2020	After Market	$-0.50	-21.95%
11/04/2019	After Market	$-0.40	-2.56%
08/01/2019	After Market	$-0.38	-31.03%
05/07/2019	After Market	$-0.30	-3.45%
02/27/2019	After Market	$-0.27	0.00%
11/06/2018	After Market	$-0.36	-9.09%
08/06/2018	After Market	$-0.34	-9.68%
05/10/2018	After Market	$-0.31	-6.90%
03/12/2018	After Market	$-0.36	-12.50%
10/31/2017	After Market	$-0.35	-2.94%
08/01/2017	After Market	$-0.37	-8.82%
05/01/2017	After Market	$-0.33	-17.86%
03/07/2017	After Market	$-0.25	0.00%
11/04/2016	Before Market	$-0.17	22.73%
08/08/2016	After Market	$-0.23	-21.05%
05/09/2016	Before Market	$-0.14	12.50%
03/10/2016	Before Market	$-0.20	0.00%
11/05/2015	Before Market	$-0.16	0.00%
08/10/2015	After Market	$-0.14	6.67%
05/11/2015	After Market	$-0.14	-27.27%
03/16/2015	After Market	$-0.18	-100.00%
11/13/2014	After Market	$-0.11	15.38%
08/08/2014	---	$-0.09	25.00%
05/28/2014	---	$-0.11	---
03/28/2014	---	$-1.50	-1,263.64%
11/27/2013	---	$-0.66	---
08/28/2013	---	$-54.94	---
03/31/2013	---	$-1.28	---
12/31/2012	---	$4.23	---
09/30/2012	---	$-0.86	---
06/30/2012	---	$-0.42	---
03/31/2012	---	$-7.39	---
12/31/2011	---	$-11.00	---
09/30/2011	---	$-7.43	---
06/30/2011	---	$-14.80	---
03/31/2011	---	$-0.78	---
12/31/2010	---	$-1.14	---
09/30/2010	---	$-0.99	---
06/30/2010	---	$-0.12	---
03/31/2010	---	$-0.00	---
12/31/2009	---	$-0.00	---
09/30/2009	---	$-0.00	---

More About Iovance Biotherapeutics Inc

Website

https://www.iovance.com

Country

USA

Full Time Employees

838

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

“Iovance Biotherapeutics Inc Earnings” Can Refer to the Iovance Biotherapeutics Inc Earnings Date

Some people say “Iovance Biotherapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Iovance Biotherapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Iovance Biotherapeutics Inc Stock on the Earnings Date

If you own Iovance Biotherapeutics Inc stock (IOVA) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Iovance Biotherapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Iovance Biotherapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Iovance Biotherapeutics Inc Earnings

You can contact us any time if you would like to ask questions about Iovance Biotherapeutics Inc earnings or anything else related to the stock market.